EGFR and non-small cell lung carcinoma: Participants in the study included adults aged 18 and older who were diagnosed with locally advanced or metastatic NSCLC, specifically those with stage IIIB, IIIC, or IV disease, or with unresectable tumors harboring EGFR exon 19 deletions or the exon 21 L858R mutation.